Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers.
Death associated protein kinase 1
Immune checkpoint inhibitors
Immune infiltration
Pan-cancer
Prognostic biomarker
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
23
07
2023
accepted:
09
01
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
epublish
Résumé
Death Associated Protein Kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase, which has been reported to be a tumor suppressor with unbalanced expression in various tissues. However, its function in tumor immunotherapy is still unclear. The online GEPIA2 database was used to support TCGA results. We explored the DAPK1 pan-cancer genomic alteration analysis using the cBioPortal web tool. The Human Protein Atlas (HPA) was employed to mine DAPK1 protein information. We verified the expression of DAPK1 in lung adenocarcinoma samples using RT-qPCR. Subsequently, the relationship between the expression of DAPK1 and the clinical stage was analyzed. We used TIMER2.0 as the primary platform for studying DAPK1-related immune cell infiltration. Associations between DAPK1 and immunotherapy biomarkers were analyzed using Spearman correlation analysis. TMB and MSI expression was also examined. Finally, we used Kaplan-Meier Plots to evaluate the relationship between DAPK1 expression and the efficacy of immunotherapy. DAPK1 is aberrantly expressed in most cancer types and has prognostic power in various cancers. Gene mutation was the most common DAPK1 alteration across pan-cancers. The DAPK1 protein was mainly localized to tumor cell centrosomes. DAPK1 was also significantly associated with immune-activated hallmarks, immune cell infiltration, and the expression of immunomodulators. Notably, DAPK1 can also significantly predict responses to anti-PD1 and anti-CTLA-4 therapy in cancer patients. Our findings suggest that DAPK1 may not only be an effective prognostic factor in cancer patients but may also function as a promising predictive immunotherapy biomarker for cancer patients treated with immune checkpoint inhibitors.
Sections du résumé
BACKGROUND
BACKGROUND
Death Associated Protein Kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase, which has been reported to be a tumor suppressor with unbalanced expression in various tissues. However, its function in tumor immunotherapy is still unclear.
METHODS
METHODS
The online GEPIA2 database was used to support TCGA results. We explored the DAPK1 pan-cancer genomic alteration analysis using the cBioPortal web tool. The Human Protein Atlas (HPA) was employed to mine DAPK1 protein information. We verified the expression of DAPK1 in lung adenocarcinoma samples using RT-qPCR. Subsequently, the relationship between the expression of DAPK1 and the clinical stage was analyzed. We used TIMER2.0 as the primary platform for studying DAPK1-related immune cell infiltration. Associations between DAPK1 and immunotherapy biomarkers were analyzed using Spearman correlation analysis. TMB and MSI expression was also examined. Finally, we used Kaplan-Meier Plots to evaluate the relationship between DAPK1 expression and the efficacy of immunotherapy.
RESULTS
RESULTS
DAPK1 is aberrantly expressed in most cancer types and has prognostic power in various cancers. Gene mutation was the most common DAPK1 alteration across pan-cancers. The DAPK1 protein was mainly localized to tumor cell centrosomes. DAPK1 was also significantly associated with immune-activated hallmarks, immune cell infiltration, and the expression of immunomodulators. Notably, DAPK1 can also significantly predict responses to anti-PD1 and anti-CTLA-4 therapy in cancer patients.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that DAPK1 may not only be an effective prognostic factor in cancer patients but may also function as a promising predictive immunotherapy biomarker for cancer patients treated with immune checkpoint inhibitors.
Identifiants
pubmed: 38787485
doi: 10.1007/s11033-024-09240-y
pii: 10.1007/s11033-024-09240-y
doi:
Substances chimiques
Death-Associated Protein Kinases
EC 2.7.11.1
DAPK1 protein, human
EC 2.7.11.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
670Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R (2019) PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol 234(2):1313–1325
pubmed: 30191996
doi: 10.1002/jcp.27172
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim 6(1):38
pubmed: 32382051
doi: 10.1038/s41572-020-0160-6
Xin YuJ, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J (2020) Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov 19(3):163–164
doi: 10.1038/d41573-019-00182-w
Singh P, Ravanan P, Talwar P (2016) Death associated protein kinase 1 (DAPK1): a regulator of apoptosis and autophagy. Front Mol Neurosci 9:46
pubmed: 27445685
pmcid: 4917528
doi: 10.3389/fnmol.2016.00046
Bialik S, Kimchi A (2006) The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 75:189–210
pubmed: 16756490
doi: 10.1146/annurev.biochem.75.103004.142615
Michie AM, Mccaig AM, Nakagawa R, Vukovic M (2010) Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 277(1):74–80
pubmed: 19878310
doi: 10.1111/j.1742-4658.2009.07414.x
Nair S, Hagberg H, Krishnamurthy R, Thornton C, Mallard C (2013) Death associated protein kinases: molecular structure and brain injury. Int J Mol Sci 14(7):13858–13872
pubmed: 23880846
pmcid: 3742222
doi: 10.3390/ijms140713858
Chen D, Zhou XZ, Lee TH (2019) Death-associated protein kinase 1 as a promising drug target in cancer and Alzheimer’s disease. Recent Pat Anticancer Drug Discov 14(2):144–157
pubmed: 30569876
pmcid: 6751350
doi: 10.2174/1574892814666181218170257
Movahhed P, Saberiyan M, Safi A, Arshadi Z, Kazerouni F, Teimori H (2022) The impact of DAPK1 and mTORC1 signaling association on autophagy in cancer. Mol Biol Rep 49(6):4959–4964
pubmed: 35083613
doi: 10.1007/s11033-022-07154-1
Yuan W, Ji J, Shu Y, Chen J, Liu S, Wu L, Zhou Z, Liu Z, Tang Q, Zhang X, Shu X (2019) Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer. J Mol Med (Berl) 97(1):89–102
pubmed: 30460377
doi: 10.1007/s00109-018-1716-8
Li L, Guo L, Wang Q, Liu X, Zeng Y, Wen Q, Zhang S, Kwok HF, Lin Y, Liu J (2017) DAPK1 as an independent prognostic marker in liver cancer. PeerJ 5:e3568
pubmed: 28740751
pmcid: 5520959
doi: 10.7717/peerj.3568
Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45(10):1113–1120
doi: 10.1038/ng.2764
Srivastava S, Hanash S (2020) Pan-cancer early detection: hype or hope? Cancer Cell 38(1):23–24
pubmed: 32531269
doi: 10.1016/j.ccell.2020.05.021
Blum A, Wang P, Zenklusen JC (2018) SnapShot: TCGA-analyzed tumors. Cell 173(2):530
pubmed: 29625059
doi: 10.1016/j.cell.2018.03.059
Barger CJ, Branick C, Chee L, Karpf AR (2019) Pan-cancer analyses reveal genomic features of FOXM1 overexpression in cancer. Cancers (Basel) 11(2):251
pubmed: 30795624
doi: 10.3390/cancers11020251
Tang Z, Kang B, Li C, Chen T, Zhang Z (2019) GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47(W1):W556–W560
pubmed: 31114875
pmcid: 6602440
doi: 10.1093/nar/gkz430
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Ritchie ME, Phipson B, Wu D, Hu Y, Law C W, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47
doi: 10.1093/nar/gkv007
Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20:16
Xie JY, Chen PC, Zhang JL, Gao ZS, Neves H, Zhang SD, Wen Q, Chen WD, Kwok HF, Lin Y (2017) The prognostic significance of DAPK1 in bladder cancer. Plos One 12(4):e0175290
doi: 10.1371/journal.pone.0175290
Wang Q, Weng S, Sun Y, Lin Y, Zhong W, Kwok HF, Lin Y (2022) High DAPK1 Expression Promotes Tumor Metastasis of Gastric Cancer. Biology 11(10):1488
doi: 10.3390/biology11101488
Picard E, Verschoor CP, Ma GW, Pawelec G (2020) Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol 11:369
pubmed: 32210966
pmcid: 7068608
doi: 10.3389/fimmu.2020.00369
Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R (2019) Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res 7(10):1570–1573
pubmed: 31405947
pmcid: 6774837
doi: 10.1158/2326-6066.CIR-19-0149
Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, Ji M, Xu L, He N, Hou P (2012) Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 413(7–8):787–794
pubmed: 22285775
doi: 10.1016/j.cca.2012.01.013
Thongchot S, Vidoni C, Ferraresi A, Loilome W, Yongvanit P, Namwat N, Isidoro C (2018) Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. Mol Carcinog 57(12):1735–1750
pubmed: 30136419
doi: 10.1002/mc.22893
Hughes LA, Melotte V, De Schrijver J, De Maat M, Smit VT, Bovee JV, French PJ, Van Den Brandt PA, Schouten LJ, De Meyer T, Van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, Van Engeland M (2013) The CpG island methylator phenotype: what’s in a name? Cancer Res 73(19):5858–5868
pubmed: 23801749
doi: 10.1158/0008-5472.CAN-12-4306
Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K (2008) Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122(3):603–608
pubmed: 17943730
doi: 10.1002/ijc.23143
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR (2019) Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20(4):840
pubmed: 30781344
pmcid: 6413095
doi: 10.3390/ijms20040840
Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L (2020) Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 13(1):29
pubmed: 32245497
pmcid: 7119170
doi: 10.1186/s13045-020-00862-w
Liu W, Ye H, Liu YF, Xu CQ, Zhong YX, Tian T, Ma SW, Tao H, Li L, Xue LC, He HQ (2018) Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncol Lett 15(4):4351–4357
pubmed: 29541203
pmcid: 5835954
Jia D, Li S, Li D, Xue H, Yang D, Liu Y (2018) Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging 10(4):592–605 (Albany NY)
pubmed: 29676997
pmcid: 5940130
doi: 10.18632/aging.101415
Yang S, Liu T, Nan H, Wang Y, Chen H, Zhang X, Zhang Y, Shen B, Qian P, Xu S, Sui J, Liang G (2020) Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. J Cell Physiol 235(2):1025–1035
pubmed: 31240705
doi: 10.1002/jcp.29018
Wang Y, Wang X, Xiong Y, Li CD, Xu Q, Shen L, Chandra Kaushik A, Wei DQ (2019) An integrated pan-cancer analysis and structure-based virtual screening of GPR15. Int J Mol Sci 20(24):6226
pubmed: 31835584
pmcid: 6940937
doi: 10.3390/ijms20246226
Cao Y, Tu Y, Xiong J, Tan S, Luo L, Wu A, Shu X, Jie Z, Li Z (2022) Retraction Note: microRNA-15b-5p encapsulated by M2 macrophage-derived extracellular vesicles promotes gastric cancer metastasis by targeting BRMS1 and suppressing DAPK1 transcription. J Exp Clin Cancer Res 41(1):213
pubmed: 35768879
pmcid: 9245310
doi: 10.1186/s13046-022-02426-x
Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349(6255):1483–1489
pubmed: 26404825
doi: 10.1126/science.aab4082
Sanz-Garcia E, Argiles G, Elez E, Tabernero J (2017) BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol 28(11):2648–2657
pubmed: 29045527
doi: 10.1093/annonc/mdx401
Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: american society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol 34(2):179–185
pubmed: 26438111
doi: 10.1200/JCO.2015.63.9674
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, Deangelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D’angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, Dematteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51(2):202–206
pubmed: 30643254
pmcid: 6365097
doi: 10.1038/s41588-018-0312-8
Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22(11):1342–1350
pubmed: 27694933
doi: 10.1038/nm.4191
Cao D, Xu H, Xu X, Guo T, Ge W (2019) High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology 8(9):e1629258
pubmed: 31428527
pmcid: 6685508
doi: 10.1080/2162402X.2019.1629258
III Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D (2017) Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(3):370–398
pubmed: 28275037
doi: 10.6004/jnccn.2017.0036
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34
pubmed: 28420421
pmcid: 5395719
doi: 10.1186/s13073-017-0424-2
Zhang J, Yu XL, Zheng GF, Zhao F (2015) DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer. Cancer Biomark 15(5):609–617
pubmed: 26406950
doi: 10.3233/CBM-150501
Graham WL, Harley JB, Alberico C, Kelln EE (1965) Absent lamina dura associated with a developmental dentin abnormality. A family study Arch Intern Med 116(6):837–841
pubmed: 5848215
doi: 10.1001/archinte.1965.03870060035008
Dai L, Ma C, Zhang Z, Zeng S, Liu A, Tang S, Ren Q, Sun Y, Xu C (2016) DAPK promoter methylation and bladder cancer risk: a systematic review and meta-analysis. PLoS ONE 11(12):e0167228
pubmed: 27907054
pmcid: 5132202
doi: 10.1371/journal.pone.0167228
Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH (2015) Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 125(7):2707–2720
pubmed: 26075823
pmcid: 4563671
doi: 10.1172/JCI70805
Guo Z, Zhou C, Zhou L, Wang Z, Zhu X, Mu X (2022) Overexpression of DAPK1-mediated inhibition of IKKbeta/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer. Cell Immunol 372:104469
pubmed: 35114597
doi: 10.1016/j.cellimm.2021.104469